Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab Meeting Abstract
| Authors: | Sanborn, R.; Gabrail, N.; Carneiro, B.; O'Hara, M.; Bordoni, R.; Gordon, M.; Khalil, D.; Hauke, R.; Taglienti, C.; Rogalski, M.; Styles, R.; Alvarado, D.; Maurer, D.; Crew, L.; Keler, T.; Yellin, M. |
| Abstract Title: | Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab |
| Meeting Title: | 37th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2022) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 10 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Nov 8-12 |
| Meeting Location: | Boston, MA |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-11-01 |
| Start Page: | A624 |
| Language: | English |
| ACCESSION: | WOS:000919423400557 |
| DOI: | 10.1136/jitc-2022-SITC2022.0596 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 596 -- Source: Wos |
